doi: 10.1093/jnci/djq350.
Epub 2010 Aug 25.
FDA increases focus on postmarketing studies
- PMID: 20739650
- DOI: 10.1093/jnci/djq350
Item in Clipboard
FDA increases focus on postmarketing studies
J Natl Cancer Inst.
.
No abstract available
Similar articles
-
Industry reneges on postmarketing trial commitments.Nat Biotechnol. 2003 Jul;21(7):718. doi: 10.1038/nbt0703-718. Nat Biotechnol. 2003. PMID: 12833074 No abstract available.
-
GlaxoSmithKline cancer drug threatens Herceptin market.Nat Biotechnol. 2005 Dec;23(12):1453-4. doi: 10.1038/nbt1205-1453. Nat Biotechnol. 2005. PMID: 16333273 No abstract available.
-
Promising drug is victim of bad business.Nat Med. 2002 Mar;8(3):199. doi: 10.1038/nm0302-199a. Nat Med. 2002. PMID: 11875472 No abstract available.
-
Post-marketing studies of new insulins: sales or science?BMJ. 2012 Jun 12;344:e3974. doi: 10.1136/bmj.e3974. BMJ. 2012. PMID: 22692652 Review. No abstract available.
-
Therapeutic monoclonal antibodies in oncology.J R Soc Med. 2005 Apr;98(4):146-52. doi: 10.1177/014107680509800403. J R Soc Med. 2005. PMID: 15805554 Free PMC article. Review. No abstract available.
Cited by
-
Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.Invest New Drugs. 2013 Apr;31(2):473-8. doi: 10.1007/s10637-012-9877-8. Epub 2012 Sep 11. Invest New Drugs. 2013. PMID: 22965890 Review.
-
The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA.Pharmacoeconomics. 2015 Jul;33(7):643-53. doi: 10.1007/s40273-015-0264-0. Pharmacoeconomics. 2015. PMID: 25686799 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
